Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies

Current Hypertension Reports

Volumn 18, Issue 7, 2016, Pages

  Lachowska, Kamila ^a   Gruchała, Marcin ^a   Narkiewicz, Krzysztof ^a   Hering, Dagmara ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cardiovascular risk; Heart failure; Interventional therapy; Mortality; Pharmacological drugs; Reflex neural mechanisms; Sympathetic nervous system activity

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IVABRADINE; METOPROLOL; MINERALOCORTICOID ANTAGONIST; REBOXETINE;

ADAPTIVE SERVO VENTILATION THERAPY; ADRENERGIC SYSTEM; BREATHING EXERCISE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CAROTID BODY; DISEASE CLASSIFICATION; DISEASE COURSE; DOWN REGULATION; HEART FAILURE; HEART HEMODYNAMICS; HOSPITALIZATION; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; KIDNEY DENERVATION; MORBIDITY; NERVE STIMULATION; NONINVASIVE VENTILATION; PHRENIC NERVE; POSITIVE END EXPIRATORY PRESSURE; PRESSORECEPTOR REFLEX; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC FUNCTION; VAGUS NERVE STIMULATION; ANIMAL; CHRONIC DISEASE; COMPLICATION; HYPERTENSION; RISK FACTOR;

ANIMALS; CHRONIC DISEASE; HEART FAILURE; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84969940539     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-016-0660-7     Document Type: Review

References (94)

1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.
2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–46.
3. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):E29–E322.
4. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44.
5. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296(18):2217–26.
6. Blair JE, Zannad F, Konstam MA, et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol. 2008;52(20):1640–8.
7. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61(4):391–403.
8. Gheorghiade M, Vaduganathan M, Ambrosy A, et al. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev. 2013;18(2):107–22.
9. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA. 2010;303(21):2141–7.
10. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92(11):3206–11.
11. Ferguson DW, Berg WJ, Sanders JS. Clinical and hemodynamic correlates of sympathetic nerve activity in normal humans and patients with heart failure: evidence from direct microneurographic recordings. J Am Coll Cardiol. 1990;16(5):1125–34.
12. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73(4):615–21.
13. Bristow MR. beta-Adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101(5):558–69.
14. Lamba S, Abraham WT. Alterations in adrenergic receptor signaling in heart failure. Heart Fail Rev. 2000;5:7–16.
15. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33(9):1058–66.
16. Colucci WS. The effects of norepinephrine on myocardial biology: implications for the therapy of heart failure. Clin Cardiol. 1998;21(12):20–4.
17. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26(5):1257–63. This study demonstrated that increased cardiac noradrenaline spillover predicted poor CV outcomes in heart failure patients.
18. Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J. 2005;26(9):906–13. This study documented the association of increased renal noradrenaline spillover and all-cause mortality, and heart transplantation in heart failure patients.
19. Setoguchi S, Stevenson LW. Hospitalizations in patients with heart failure: who and why. J Am Coll Cardiol. 2009;54(18):1703–5.
20. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341(8):577–85.
21. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689–97.
22. Mancia G, Dell’Oro R, Quarti-Trevano F, Scopelliti F, Grassi G. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens Suppl. 2006;24(1):S51–6.
23. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation. 1984;69(3):451–60.
24. Mark AL. Sympathetic dysregulation in heart failure: mechanisms and therapy. Clin Cardiol. 1995;18(3 Suppl I):I3–8.
25. Mortara A, LaRovere MT, Pinna GD, et al. Arterial baroreflex modulation of heart rate in chronic heart failure—clinical and hemodynamic correlates and prognostic implications. Circulation. 1997;96(10):3450–8.
26. Somers VK, Mark AL, Abboud FM. Interaction of baroreceptor and chemoreceptor reflex control of sympathetic nerve activity in normal humans. J Clin Investig. 1991;87(6):1953–7.
27. van de Borne P, Oren R, Anderson EA, Mark AL, Somers VK. Tonic chemoreflex activation does not contribute to elevated muscle sympathetic nerve activity in heart failure. Circulation. 1996;94(6):1325–8. First study demonstrating the role of peripheral chemoreflexes in heart failure.
28. Narkiewicz K, Pesek CA, van de Borne P, Kato M, Somers VK. Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure. Circulation. 1999;100(3):262–7. First study demonstrating the role of central chemoreflexes in heart failure.
29. Despas F, Franchitto N, Labrunee M, Galinier M, Senard JM, Pathak A. Tonic chemoreflex activation contributes to increased sympathetic nerve activity in heart failure-related anemia. Circulation 2010; 122(21).
30. Despas F, Lambert E, Vaccaro A, et al. Peripheral chemoreflex activation contributes to sympathetic baroreflex impairment in chronic heart failure. J Hypertens. 2012;30(4):753–60.
31. Yumino D, Wang HQ, Floras JS, et al. Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction. J Card Fail. 2009;15(4):279–85.
32. van de Borne P, Oren R, Abouassaly C, Anderson E, Somers VK. Effect of Cheyne-Stokes respiration on muscle sympathetic nerve activity in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1998;81(4):432–6.
33. Hanly PJ, Zuberi-Khokhar NS. Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure. Am J Respir Crit Care. 1996;153(1):272–6.
34. Lanfranchi PA, Braghiroli A, Bosimini E, et al. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation. 1999;99(11):1435–40. First study demonstrating that the apnoea/hypopnea index is a powerful independent predictor of poor prognosis in clinically stable patients with chronic heart failure.
35. Brack T, Thuer I, Clarenbach CF, et al. Daytime Cheyne-Stokes respiration in ambulatory patients with severe congestive heart failure is associated with increased mortality. Chest. 2007;132(5):1463–71.
36. Sin DD, Logan AG, Fitzgerald FS, Liu PP, Bradley TD. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation. 2000;102(1):61–6.
37. Ponikowski P, Chua TP, Anker SD, et al. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation. 2001;104(5):544–9. First study linking augmented peripheral chemosensitivity to adverse prognosis in patients with chronic heart failure.
38. Shepherd JT. Heart failure: role of cardiovascular reflexes. Cardioscience. 1990;1(1):7–12.
39. Hering D, Schlaich M. The role of central nervous system mechanisms in resistant hypertension. Curr Hypertens Rep. 2015;17(8):58.
40. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311(13):819–23.
41. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22(13):1136–43.
42. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 1997;15(1):3–17.
43. Kannel WB, Kannel C, Paffenbarger Jr RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J. 1987;113(6):1489–94.
44. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens. 1997;11 Suppl 1:S19–27.
45. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109(5):685–92.
46. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352(19):1951–8.
47. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26(10):967–74.
48. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29(10):1327–34.
49. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001;103(10):1428–33.
50. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65–75.
51. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817–21.
52. Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376(9744):886–94. First study demonstrating that lowering heart rates with ivabradine improves cardiovascular outcomes.
53. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-HEART). Circulation. 1998;98(15):1510–6.
54. Moore RK, Groves DG, Barlow PE, et al. Heart rate turbulence and death due to cardiac decompensation in patients with chronic heart failure. Eur J Heart Fail. 2006;8(6):585–90.
55. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med. 2010;362(3):228–38.
56. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378(9792):704–12.
57. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353(9146): 9–13.
58. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169): 2001–7.
59. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–8.
60. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.
61. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284(2):H676–82.
62. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64(16):1757–65.
63. Bohm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol Off J German Cardiac Soc. 2013;102(1):11–22.
64. Komajda M, Bohm M, Borer JS, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail. 2014;16(7):810–6.
65. Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59(22):1938–45.
66. Komajda M, Bohm M, Borer J, et al. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine’s effects in patients with chronic heart failure. Eur J Heart Fail. 2013;15(1):79–84.
67. Schroeder C, Heusser K, Zoerner AA, et al. Pacemaker current inhibition in experimental human cardiac sympathetic activation: a double-blind, randomized, crossover study. Clin Pharmacol Ther. 2014;95(6):601–7.
68. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091–9.
69. Parati G, Izzo Jr JL, Gavish B. Respiration and blood pressure. In: Izzo Jr J, Sica D, Black HR, editors. Hypertension primer. Baltimore: Lippincott, Williams, and Wilkins; 2008. p. 136–8. Chapter 143.
70. Bernardi L, Spadacini G, Bellwon J, Hajric R, Roskamm H, Frey AW. Effect of breathing rate on oxygen saturation and exercise performance in chronic heart failure. Lancet. 1998;351(9112):1308–11. First study demonstrating the effects of slow breathing in chronic heart failure.
71. Narkiewicz K, van de Borne P, Montano N, Hering D, Kara T, Somers VK. Sympathetic neural outflow and chemoreflex sensitivity are related to spontaneous breathing rate in normal men. Hypertension. 2006;47(1):51–5.
72. Raupach T, Bahr F, Herrmann P, et al. Slow breathing reduces sympathoexcitation in COPD. Eur Respir J. 2008;32(2):387–92.
73. Seals DR, Suwarno NO, Dempsey JA. Influence of lung volume on sympathetic nerve discharge in normal humans. Circ Res. 1990;67(1):130–41.
74. Goso Y, Asanoi H, Ishise H, et al. Respiratory modulation of muscle sympathetic nerve activity in patients with chronic heart failure. Circulation. 2001;104(4):418–23.
75. Hering D, Kucharska W, Kara T, Somers VK, Parati G, Narkiewicz K. Effects of acute and long-term slow breathing exercise on muscle sympathetic nerve activity in untreated male patients with hypertension. J Hypertens. 2013;31(4):739–46.
76. Parati G, Malfatto G, Boarin S, et al. Device-guided paced breathing in the home setting effects on exercise capacity, pulmonary and ventricular function in patients with chronic heart failure: a pilot study. Circ Heart Fail. 2008;1(3):178–83.
77. Davies JE, Manisty CH, Petraco R, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013;162(3):189–92. First study demonstrating the feasibility and efficacy or renal denervation in heart failure.
78. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal trial. J Am Soc Hypertens. 2012;6(2):152–8.
79. Scheffers IJM, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56(15):1254–8.
80. Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270–6.
81. Gronda E, Seravalle G, Brambilla G, et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail. 2014;16(9):977–83. First study demonstrating the feasibility and effects of baroreflex activation therapy on muscle sympathetic nerve activity and haemodynamics in heart failure.
82. Gronda E, Seravalle G, Trevano FQ, et al. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction. J Hypertens. 2015;33(8):1704–8.
83. Paton JFR, Sobotka PA, Fudim M, et al. The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension. 2013;61(1):5−+.
84. Niewinski P, Janczak D, Rucinski A, et al. Carotid body removal for treatment of chronic systolic heart failure. Int J Cardiol. 2013;168(3):2506–9. First case report demonstrating the feasibility and efficacy of carotid body removal in a patient with heart failure.
85. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure—pathophysiology and potential implications for therapy. Circulation. 2008;118(8):863–71.
86. Zhang Y, Popovic ZB, Bibevski S, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail. 2009;2(6):692–9.
87. Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail. 2008;10(9):884–91. First study demonstrating the feasibility and efficacy of vagal nerve stimulation in heart failure.
88. Zannad F, De Ferrari GM, Tuinenburg AE, et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J. 2015;36(7):425–33.
89. Javaheri S, Parker TJ, Wexler L, Liming JD, Lindower P, Roselle GA. Effect of theophylline on sleep-disordered breathing in heart failure. N Engl J Med. 1996;335(8):562–7.
90. Brown LK, Javaheri S. Adaptive servo-ventilation for the treatment of central sleep apnea in congestive heart failure: what have we learned? Curr Opin Pulm Med. 2014;20(6):550–7.
91. Javaheri S, Sands SA, Edwards BA. Acetazolamide attenuates Hunter-Cheyne-Stokes breathing but augments the hypercapnic ventilatory response in patients with heart failure. Ann Am Thorac Soc. 2014;11(1):80–6.
92. Ponikowski P, Javaheri S, Michalkiewicz D, et al. Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. Eur Heart J. 2012;33(7):889–94. First study demonstrating the feasibility and efficacy of phrenic nerve stimulation in heart failure patients with central sleep apnoea.
93. Zhang X, Ding N, Ni B, Yang B, Wang H, Zhang SJ. Safety and feasibility of chronic transvenous phrenic nerve stimulation for treatment of central sleep apnea in heart failure patients. Clin Respir J 2015.
94. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015;373(12):1095–105. First study to demonstrate an increase risk of cardiovascular death in heart failure patients with central sleep apnoea following a therapy with adaptive servo-ventilation.